Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
AIMS: Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor deficits and degeneration of dopaminergic neurons. Caused by a number of genetic and environmental factors, mitochondrial dysfunction and oxidative stress play a role in neurodegeneration in PD. By selectively knocking out mitochondrial transcription factor A (TFAM) in dopaminergic neurons, the transgenic MitoPark mice recapitulate many signature features of the disease, including progressive motor deficits, neuronal loss, and protein inclusions. In the present study, we evaluated the neuroprotective efficacy of a novel mitochondrially targeted antioxidant, Mito-apocynin, in MitoPark mice and cell culture models of neuroinflammation and mitochondrial dysfunction. RESULTS: Oral administration of Mito-apocynin (10 mg/kg, thrice a week) showed excellent central nervous system bioavailability and significantly improved locomotor activity and coordination in MitoPark mice. Importantly, Mito-apocynin also partially attenuated severe nigrostriatal degeneration in MitoPark mice. Mechanistic studies revealed that Mito-apo improves mitochondrial function and inhibits NOX2 activation, oxidative damage, and neuroinflammation. INNOVATION: The properties of Mito-apocynin identified in the MitoPark transgenic mouse model strongly support potential clinical applications for Mito-apocynin as a viable neuroprotective and anti-neuroinflammatory drug for treating PD when compared to conventional therapeutic approaches. CONCLUSION: Collectively, our data demonstrate, for the first time, that a novel orally active apocynin derivative improves behavioral, inflammatory, and neurodegenerative processes in a severe progressive dopaminergic neurodegenerative model of PD. Antioxid. Redox Signal. 27, 1048-1066.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Microglial Activation and Chronic Neurodegeneration
Lull, M. E., & Block, M. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.014 · Cited by 1,047 · cited 1×
“Reactive mi-crogliosis results from stressed neurons secreting factors that activate microglia, beginning the cycle of neuroinflammation and neuronal damage underlying neurodegenerative diseases (4, 42, 45).”
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Cross talk between mitochondria and NADPH oxidases
Dikalov, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.033 · Cited by 783 · cited 2×
“However, their involvement in PD is potentially more complex, involving other contributing factors such as protein aggregation and mitochondrial dysfunction (13, 15, 20).”
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605 · cited 1×
“MitoPark mice were created by selective inactivation of mitochondrial transcription factor A (TFAM) in the nigrostriatal pathway (22).”
Morrison, H. W., & Filosa, J. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-4 · Cited by 506 · cited 1×
“ImageJ software was used to count microglial cells, adjust threshold, convert images to binary, skeletonize, and analyze skeleton (49).”
Cochemé, H. M., Quin, C., McQuaker, S. J., Cabreiro, F., Logan, A., Prime, T. A., Abakumova, I., Patel, J. V., Fearnley, I. M., James, A. M., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.003 · Cited by 313 · cited 3×
“In addition, LC-MS-based monitoring of the conversion of the o-MitoPhB(OH)2 probe into the phenolic product (o-MitoPhOH) (10, 11, 74, 75) indicates significant suppression of mitochondrial oxidant levels (Fig.”
New Insights on NOX Enzymes in the Central Nervous System
Nayernia, Z., Jaquet, V., & Krause, K.-H. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5703 · Cited by 279
Qin, L., Liu, Y., Hong, J., & Crews, F. T. (2013) · Glia · doi:10.1002/glia.22479 · Cited by 271 · cited 2×
“In animal models of PD in which proinflammatory enzymes are elevated, anti-inflammatory therapies have successfully modulated the neurodegenerative process (32, 56).”
Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression
Wang, J., Silva, J. P., Gustafsson, C. M., Rustin, P., & Larsson, N.-G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061038798 · Cited by 245
Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury
Dohi, K., Ohtaki, H., Nakamachi, T., Yofu, S., Satoh, K., Miyamoto, K., Song, D., Tsunawaki, S., Shioda, S., & Aruga, T. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-41 · Cited by 188 · cited 1×
“Neuroinflammation is now recognized to play a key role in dopaminergic neurodegeneration in human PD patients and in mouse models (17, 53, 66).”
Case, A. J., Li, S., Basu, U., Tian, J., & Zimmerman, M. C. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00974.2012 · Cited by 96
Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease
Fifel, K., & Cooper, H. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.024 · Cited by 80 · cited 1×
“Although circadian and cognitive changes occur in MitoPark mice (25, 43), the nonmotor Parkinsonian phenotype of these mice still needs to be fully characterized.”
Chen, S.-H., Oyarzabal, E. A., & Hong, J.-S. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.10.001 · Cited by 76 · cited 2×
“essential for maintaining chronic neuroinflammation, which potentiates the neurodegenerative process through oxidative stress (9, 52).”
Belin, A. C., Björk, B. F., Westerlund, M., Galter, D., Sydow, O., Lind, C., Pernold, K., Rosvall, L., Håkansson, A., Winblad, B., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.05.010 · Cited by 48 · cited 1×
“Although the MitoPark model, with TFAM knocked out in the nigrostriatal pathway, does not mirror any specific genetic mutation associated with PD, both TFAM and mitochondrial DNA changes have been implicated in aging and PD (2, 29, 30, 54).”
Cited by
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Self-citationMitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
New insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 364
Mitochondrial Calcium: Effects of Its Imbalance in Disease
Matuz-Mares, D., González-Andrade, M., Araiza-Villanueva, M. G., Vilchis-Landeros, M. M., & Vázquez-Meza, H. (2022) · Antioxidants · doi:10.3390/antiox11050801 · Cited by 266
Sarkar, S., Rokad, D., Malovic, E., Luo, J., Harischandra, D. S., Jin, H., Anantharam, V., Huang, X., Lewis, M., Kanthasamy, A., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat9900 · Cited by 171
“13 of 16 IHC and immunocytochemistry IHC was performed on striatal sections as described in our previous publications (6, 8, 100).”
MethodSelf-citation
Metadata
- Authors
- Langley, M., Ghosh, A., Charli, A., Sarkar, S., Ay, M., Luo, J., Zielonka, J., Brenza, T., Bennett, B., Jin, H., Ghaisas, S., Schlichtmann, B., Kim, D., Anantharam, V., Kanthasamy, A., Narasimhan, B., Kalyanaraman, B., & Kanthasamy, A. G.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2017-11-10
- Volume
- 27
- Issue
- 14
- Pages
- 1048-1066
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2607248985
- Cited by
- 130
- References
- 16
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.